Biotechnology company Convergent Therapeutics will present a prostate cancer research findings at the American Society of Clinical Oncology (ASCO) annual meeting, June 2 to 6 in Chicago.
The research will describe the company's CONV01-α (actinium-225 J591), a prostate-specific membrane antigen (PSMA)-targeted monoclonal antibody linked to actinium-225. It will be presented June 3 by Dr. Scott Tagawa from Weill Cornell Medicine and will also be available on demand.
![A 53-year-old patient (patient number four) with a recurrent pituitary adenoma with extension of a cystic component of disease to the medial temporal lobe apparent on MRI (contoured in blue), and extension of disease to the left sphenoid bone and orbital apex apparent on [68Ga]Ga-DOTA-TATE (contoured in yellow).](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/04/pituitary-tumor.QGsEnyB4bU.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
